Prestige Biologics Balance Sheet Health
Financial Health criteria checks 1/6
Prestige Biologics has a total shareholder equity of ₩99.8B and total debt of ₩160.0B, which brings its debt-to-equity ratio to 160.3%. Its total assets and total liabilities are ₩305.8B and ₩206.0B respectively.
Key information
160.3%
Debt to equity ratio
₩159.97b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩45.43b |
| Equity | ₩99.80b |
| Total liabilities | ₩205.95b |
| Total assets | ₩305.75b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A334970's short term assets (₩70.2B) do not cover its short term liabilities (₩89.1B).
Long Term Liabilities: A334970's short term assets (₩70.2B) do not cover its long term liabilities (₩116.9B).
Debt to Equity History and Analysis
Debt Level: A334970's net debt to equity ratio (114.8%) is considered high.
Reducing Debt: A334970's debt to equity ratio has reduced from 173.4% to 160.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A334970 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A334970 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.